These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 21825009)

  • 21. Gastrointestinal stromal tumors.
    Antonescu C
    Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C-kit, GIST, and imatinib.
    Siehl J; Thiel E
    Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
    Gebreyohannes YK; Schöffski P; Van Looy T; Wellens J; Vreys L; Cornillie J; Vanleeuw U; Aftab DT; Debiec-Rychter M; Sciot R; Wozniak A
    Mol Cancer Ther; 2016 Dec; 15(12):2845-2852. PubMed ID: 27777285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
    Hong JL; Li J; Li J; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1.
    Nakatani H; Kobayashi M; Jin T; Taguchi T; Sugimoto T; Nakano T; Hamada S; Araki K
    Cancer Sci; 2005 Feb; 96(2):116-9. PubMed ID: 15723656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
    Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L
    Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.
    Wagner AJ; Chugh R; Rosen LS; Morgan JA; George S; Gordon M; Dunbar J; Normant E; Grayzel D; Demetri GD
    Clin Cancer Res; 2013 Nov; 19(21):6020-9. PubMed ID: 24045182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
    Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
    Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Establishment and pathologic analysis of imatinib-resistant gastrointestinal stromal tumor xenografts].
    Zheng S; Wang XJ; Jia J; Pan YL; Tao DY; Lu HS; Huang KE
    Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):176-80. PubMed ID: 22800481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.
    Sakurama K; Noma K; Takaoka M; Tomono Y; Watanabe N; Hatakeyama S; Ohmori O; Hirota S; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Tanaka N; Naomoto Y
    Mol Cancer Ther; 2009 Jan; 8(1):127-34. PubMed ID: 19139121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
    Serrano C; Mariño-Enríquez A; Tao DL; Ketzer J; Eilers G; Zhu M; Yu C; Mannan AM; Rubin BP; Demetri GD; Raut CP; Presnell A; McKinley A; Heinrich MC; Czaplinski JT; Sicinska E; Bauer S; George S; Fletcher JA
    Br J Cancer; 2019 Mar; 120(6):612-620. PubMed ID: 30792533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
    Demetri GD; Heinrich MC; Fletcher JA; Fletcher CD; Van den Abbeele AD; Corless CL; Antonescu CR; George S; Morgan JA; Chen MH; Bello CL; Huang X; Cohen DP; Baum CM; Maki RG
    Clin Cancer Res; 2009 Sep; 15(18):5902-9. PubMed ID: 19737946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
    Zook P; Pathak HB; Belinsky MG; Gersz L; Devarajan K; Zhou Y; Godwin AK; von Mehren M; Rink L
    Clin Cancer Res; 2017 Jan; 23(1):171-180. PubMed ID: 27370604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
    Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
    Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
    Zhao J; Quan H; Xu Y; Kong X; Jin L; Lou L
    Cancer Sci; 2014 Jan; 105(1):117-25. PubMed ID: 24205792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors.
    Hsueh YS; Yen CC; Shih NY; Chiang NJ; Li CF; Chen LT
    Autophagy; 2013 Feb; 9(2):220-33. PubMed ID: 23196876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
    Liu W; Zeng X; Yin Y; Li C; Yang W; Wan W; Shi L; Wang G; Tao K; Zhang P
    Gastric Cancer; 2020 Jan; 23(1):39-51. PubMed ID: 31197522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.